Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC 50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIV ADA , OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral drugs (ARVs). Cabotegravir sodium can be used to research AIDS.
Cabotegravir (GSK-1265744) 在体外抑制 HIV-1 整合酶催化的链转移反应,IC50 为 3.0 nM。在 PBMCs中对 HIV-1 Ba-L 的抗病毒 EC50为 0.22 nM,对 NL432 的EC50 为 0.34 nM。在 MT-4 细胞中,用CellTiter-Glo测得的EC50 为 0.57 nM, MTT测得的EC50 为1.3 nM,在使用伪型自灭活病毒的 PHIV 测定中EC50为0.5 nM。 has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay
体内研究(In Vivo)
Cabotegravir 在小鼠中的半衰期长达 54 天。
Cabotegravir (25 or 50 mg/kg; i.v.; single dose or twice) 保护 SIVmac251 对猕猴 (Macaques) 的感染。 has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
ClinicalTrial
参考文献
[1]. Zhou T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018 Jan;151:53-65.[2]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2016;46(5):445-56.
溶解度数据
In Vitro: DMSO : 6.9 mg/mL (16.15 mM; ultrasonic and warming and heat to 60°C)配制储备液